RxDoctor Payments Data

Megan Mezera, MD

Radiation Oncology · Camden, NJNPI 1477865426

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,650 of the $4,171 with a category attached, or 87.5%. Elekta, Inc. accounts for 92.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $4,007 and has fallen 98.5% since, to $58 in 2025. Among radiation oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,171in general payments, 2019–2025

Across 17 payments — averaging $245.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Elekta, Inc.$4K
  • Novocure Inc.$223
  • Novartis$44
  • Bayer$22
  • AstraZeneca$20
  • Regeneron Healthcare Solutions, Inc.$16

What the payments were for

  • Travel & lodging$3,65087%
  • Food & beverage$52113%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,171 in reported general payments places this provider in the 90th percentile of 132 radiation oncology providers in New Jersey.

See all radiation oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$172,235
Medicare patients
255
Services billed
1,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pentoxifylline11$261
Lidocaine Hcl ViscousLidocaine Hcl35$119

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →